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  B13 analogues are being considered as therapeutic agents for cancer cells, since B13 is a ceramide 
analogue and inhibits ceramidase to promote apoptosis in cancer cells. B13 sulfonamides are assumed 
to have biological activity similar to B13, since they are made by bioisosterically substituting the 
carboxyl moiety of B13 with sulfone group. Twenty B13 sulfonamides were evaluated for their in vitro 
cytotoxicities against human colon cancer HT-29 and lung cancer A549 cell lines using MTT assays. 
Replacement of the amide group with a sulfonamide group increased cytotoxicity in both cancer cell 
lines. The sulfonamides with long alkyl chains exhibited activities two to three times more potent 
than that of B13 and compound (15) had the most potent activity with IC50 values o f  27 and  28.7μM 
for HT-29 and A549, respectively. The comparative molecular field analysis (CoMFA) and comparative 
molecular similarity indices analysis (CoMSIA) were used to carry out QSAR molecular modeling of 
these compounds. The predictive CoMSIA models for HT-29 and A549 gave cross-validated q2 values 
of 0.703 and 0.830, respectively. From graphical analysis of these models, we suppose that the 
stereochemistry of 1,3-propandiol is not important for activity and that introduction of a sulfonamide 
group and long alkyl chains into B13 can increase cytotoxicity.
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INTRODUCTION
  Sphingolipids, such as ceramide and its metabolites, have 
recently been recognized as important compounds as secon-
dary messengers involved in signal transduction. They acti-
vate ceramide-mediated phosphatases and kinases to stim-
ulate the apoptotic pathways and inhibit cancer cell growth 
[1-3]. They are also involved in cell division, differentiation, 
inflammation, and smooth muscle cell relaxation [4-7]. 
Some anticancer agents were reported to induce intra-
cellular ceramide accumulation [8], which led to cell cycle 
arrest and apoptosis in tumor cells [9-11]. However, cellular 
ceramide is rapidly removed by ceramide metabolizing en-
zymes like ceramidase.
  Because ceramide induces apoptosis in cancer cells, ce-
ramide analogues are being considered as therapeutic 
agents for cancer cells [12-17]. The introduction of a phenyl 
ring into the long alkyl chain moiety of ceramide as in 
D-e-MAPP was shown to enhance ceramidase inhibition 
and increase intracellular ceramide concentration [18,19]. 
The aromatic analogues of ceramide, such as D-e-MAPP 
with 1S, 2R configuration and B13 with 1R, 2R config-
uration rather than 2S, 3R configuration of natural ceram-
ide, inhibit ceramidase to induce apoptosis (Fig. 1). In this 
way, they exhibit potent cytotoxicity against various cancer 
cells including leukemia, colon, and prostate cancer cells 
[20-25]. Furthermore, B13 showed selective cytotoxicity to-
ward malignant cells but not normal cells and prevented 
colon cancer cells from the transition to metastasis in a 
nude mouse model [9].
  The amide group of ceramide can be isosterically replaced 
by urea or an amine group to increase inhibitory activity 
against ceramidase and to promote cytotoxicity [25]. The 
B13 sulfonamides are assumed to exhibit biological activ-
ities similar to that of B13, since they were made by bio-
isosterically substituting the carboxyl moiety in B13 with 
a sulfone group. Sulfonamides are also known to have vari-
ous biological activities acting as hypoglycemic, diuretic, 
and antibacterial agents [26-28]. Recently, some sulfona-
mides have been reported to demonstrate anticancer activ-
ity [29-32].
  As a continuation of our previous reported work [33] and 
as an extension of those findings, we report here on the 
cytotoxicities of twenty B13 sulfonamide analogues against 
human colon and lung cancer cell lines and evaluate the 
influence of the stereochemistry of 1,3-propandiol, the p-ni-424 SKC Lee, et al
Fig. 1. Structure of ceramide and 
B13 analogues.
tro group in the phenyl ring, and alkyl chain length in the 
sulfonamide moiety. We also carry out QSAR analysis to 
investigate the relationship between the structural features 
and cytotoxicity of B13 sulfonamide analogues.
METHODS
Chemicals
  Phosphate-buffered saline (PBS) was bought from Boeh-
ringer Mannheim. Dimethyl sulfoxide (DMSO), 3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), 
and other reagents were obtained from Sigma.
In vitro cytotoxic assay
  The cytotoxic activities of B13 sulfonamides which were 
synthesized in our lab were estimated in two human tumor 
cell lines: colon cancer HT-29 and lung cancer A549. The 
results from the cytotoxic assays are illustrated in Table 
1 and a description of the MTT-based colorimetric assay 
used is included in the legend for that Table [34].
Data sets and values
   Twenty-one compounds were used to perform QSAR 
analysis. The molecular structures of the training and test 
sets are shown in Table 1. The data set was divided into 
two groups. Based on their different alkyl chain lengths and 
R, S configurations at C1 and C2, four compounds (1, 10, 
12, 18) were selected for the test set, which was used for 
external validation of the QSAR models. The rest of the 
17 compounds including B13 were used for the training set. 
All IC50 values were converted into pIC50 (−log IC50) values 
which were then used as the dependent values to derive 
CoMFA and CoMSIA.
Molecular modeling
  We used Sybyl-X 1.2 program for modeling molecules, 
performing partial least squares (PLS), and conducting 
CoMFA and CoMSIA [35]. Molecular structures were de-
signed with a sketch tool and optimized using a TRIPOS 
force field with the Gasteiger Huckel charges and con-
jugated gradient method. The conformations with low en-
ergy were analyzed by simulated annealing and were 
aligned using the fitting atoms method. The propyl moiety 
(C1-C2-C3) marked as a bold line in Table 1 was used as 
a common substructure and the most active compound (15) 
was used as a template molecule in alignment.
CoMFA and CoMSIA
  CoMFA was executed in the steric and electrostatic fields 
with the default values. Aligned molecules were put into 
the three dimensional cubic lattice with a grid spacing of 
2.0  Å. The energy cutoff was the default value of 30 
kcal/mol. The Lennard-Jones potential and Coulombic po-
tential were applied to calculate the steric and electrostatic 
field energies of CoMFA, respectively. The sp
3 probe carbon 
atom with a charge of ＋1 and a Van der Waals radius of 
1.52 Å was used to create the CoMFA steric and electro-
static fields. The CoMSIA concerns five properties (steric, 
electrostatic, hydrophobic, hydrogen bond acceptor, and hy-
drogen bond donor fields) using a common probe atom with 
radius 1.0 Å, charge ＋1, hydrophobicity ＋1, hydrogen 
bond donating ＋1, and hydrogen bond accepting ＋1.
Partial least square (PLS) analysis
  In the PLS analysis, the leave-one-out method of cross- Cytotoxicities and QSAR of B13 Sulfonamides 425
Table 1. Structures and in vitro cytotoxicities of B13 sulfonamide analogues
Compounds R1 R2 R3 Configuration
Cytotoxicity IC50 ( μM)
Colon cancer (HT-29) Lung cancer (A549)
 1H H C 7H15 1R, 2S 191.5 207.3
 2H H C 8H17 1R, 2S 93.8 148.7
 3H H C 9H19 1R, 2S 83.2 90.5
 4H H C 11H23 1R, 2S 44.2 46.0
 5H H C 13H27 1R, 2S 35.9 49.3
 6H H C 7H15 1S, 2R 183.0 205.7
 7H H C 8H17 1S, 2R 96.6 96.6
 8H H C 9H19 1S, 2R 60.0 73.0
 9H H C 11H23 1S, 2R 37.8 74.2
10 H H C13H27 1S, 2R 39.2 80.7
11 OH NO2 C7H15 1R, 2R 101.0 ＞267.3
12 OH NO2 C8H17 1R, 2R 53.3 84.6
13 OH NO2 C9H19 1R, 2R 27.9 42.7
14 OH NO2 C11H23 1R, 2R 25.7 41.1
15 OH NO2 C13H27 1R, 2R 27.0 28.7
16 OH NO2 C7H15 1S, 2S 161.6 267.3
17 OH NO2 C8H17 1S, 2S 100.3 89.0
18 OH NO2 C9H19 1S, 2S 52.2 69.1
19 OH NO2 C11H23 1S, 2S 61.3 40.9
20 OH NO2 C13H27 1S, 2S 30.8 30.8
B13 1R, 2R 68.4 94.2
The cells were plated at a density of approximately 1×10
4 cells/well in 96-well plates. Each well contained 180μl of medium into 
which 20μl of 10×concentration of prepared compounds or PBS were added. After 96h of culture, 0.1mg of MTT was added to 
each well and incubated at 37
oC for 4 h. The plates were centrifuged at 450×g to precipitate the formazan crystals. The medium 
was removed and 150μl of DMSO was added to each well to dissolve the formazan. In this assay, MTT was converted to blue 
formazan by mitochondrial dehydrogenase. The intensity of the blue color was measured with a microplate reader at a wavelength 
of 540 nm. The mean measured values are expressed as the IC50, the concentration that reduced the optical density of the treated 
cells by 50% with respect to the untreated controls.
validation was carried out to determine the optimum num-
ber of components, which were then used for the non- 
cross-validated analysis. In the leave-one-out method, one 
compound was removed from the data set and its biological 
activity was predicted with the model derived from the rest 
of the data set.
RESULTS
In vitro cytotoxic activity
  The cytotoxicities of twenty-one B13 sulfonamides against 
human colon cancer HT-29 and lung cancer A549 cell lines 
were estimated in vitro. Their biological activities are sum-
marized in Table 1 and B13 itself showed moderate cytotox-
icity with IC50 values of 68.4 and 94.2μM for HT-29 and 
A549 cells, respectively. In colon cancer HT-29 cells, most 
of the sulfonamides except for the short alkyl chain (C7H15 
and C8H17) compounds (1, 2, 6, 7, 11, 16, 17) showed more 
potent activities than B13. The cytotoxicities of the long 
alkyl chain (C13H27) analogues (5, 10, 15, 20) were increased 
two times that of B13 to give IC50 values of 35.9, 39.2, 27, 
and 30.8μM, respectively, in HT-29 cells. Compounds (11∼
20) with a C3-OH and para nitro group in the phenyl ring 
had stronger activities than compounds (1∼10) which did 
not have these groups. For lung cancer A549 cells, the long 
alkyl chain compounds exhibited more potent cytotoxicities 
than the short alkyl chain compounds. Some of the long 
alkyl chains (C11H23 and C13H27) analogues (4, 5, 14, 15, 
19, 20) showed almost two-fold increases in activity with 
IC50 values of 46, 49.3, 41.1, 28.7, 40.9, and 30.8μM, 
respectively. Compounds (5, 10, 15, 20) with long alkyl 
chain (C13H27) were much more active than B13 against 
both tumor cell lines and exhibited IC50 values of 35.9, 39.2, 
27, and 30.8μM, respectively, against colon cancer HT-29 
cell lines and 49.3, 80.7, 28.7, and 30.8μM, respectively, 
against lung cancer A549 cell lines. The IC50 values of the 
other compounds ranged from 25.7 to 191.5μM for HT-29 
cells and 40.9 to 267.3μM for A549 cells.
3D-QSAR analysis
  T h e  s t a t i s t i c a l  data from CoMFA and CoMSIA models 
are illustrated in Table 2. All CoMFA and CoMSIA models 
were based on the training set of 17 compounds and the 
test set of 4 compounds.426 SKC Lee, et al
Table 2. Statistical data of CoMFA and CoMSIA models
Field
a q
2b N
c SEP
d r
2
ncv
e SEE
f F
g r
2
pred
h Contributions
a
SE HDA
Colon cancer (HT-29 cells)
  C o M F A
    SE 0.198 3 0.273 0.987 0.035 329.619 0.446 0.554
  C o M S I A
    HD 0.701 4 0.173 0.985 0.039 198.589 0.605 0.395
    HA 0.678 4 0.180 0.984 0.040 187.848 0.587 0.413
    DA 0.444 3 0.227 0.935 0.078 62.026 0.400 0.600
    SHA 0.556 4 0.211 0.991 0.030 327.721 0.249 0.444 0.307
    EHA 0.495 4 0.225 0.988 0.035 247.728 0.365 0.398 0.237
    HDA 0.703 4 0.173 0.992 0.027 396.375 0.929 0.442 0.269 0.290
Lung cancer (A549 cells)
  C o M F A
    SE 0.442 3 0.255 0.990 0.034 426.595 0.420 0.580
  C o M S I A
    EH 0.735 4 0.183 0.998 0.017 1,364.022 0.480 0.520
    EA 0.509 3 0.222 0.988 0.035 341.530 0.560 0.440
    HA 0.830 4 0.147 0.990 0.036 290.264 0.832 0.587 0.413
    SHA 0.705 4 0.193 0.992 0.032 373.955 0.223 0.456 0.321
    EHA 0.772 4 0.170 0.997 0.019 1,033.608 0.319 0.681
    HDA 0.777 4 0.168 0.992 0.031 382.732 0.496 0.190 0.314
aFields used (S, steric; E, electrostatic; H, hydrophobic; D, H-bond donor; A, H-bond acceptor); 
bq
2, cross-validated correlation coeffi-
cient from leave-one-out (LOO); 
cN, optimum number of components; 
dSEP, standard error of prediction; 
er
2
ncv, non-cross-validated 
correlation coefficient; 
fSEE, standard error of estimate; 
gF, F-test value; 
hr
2
pred, predicted correlation coefficient.
Table 3. Actual versus  predicted cytotoxicities (pIC50) of the training set
Compounds
Colon cancer cells (HT-29 cells) Lung cancer cells (A549 cells)
Actual
a Predicted
b Residual
c Actual
a Predicted
b Residual
c
 2 4.03 4.03 0.00 3.83 3.83 0.00
 34 . 0 8 4 . 1 0 −0.02 4.04 4.09 −0.05
 44 . 3 6 4 . 3 8 −0.02 4.34 4.30 0.04
 5 4.44 4.40 0.04 4.31 4.26 0.05
 6 3.74 3.74 0.00 3.69 3.70 −0.01
 74 . 0 1 4 . 0 3 −0.02 4.02 3.96 0.06
 84 . 2 2 4 . 2 4 −0.02 4.14 4.14 −0.01
 9 4.42 4.39 0.03 4.13 4.14 −0.01
11 4.00 4.02 −0.03 3.57 3.62 −0.04
13 4.55 4.53 0.03 4.37 4.37 0.00
14 4.59 4.59 0.00 4.39 4.42 −0.03
15 4.57 4.59 −0.02 4.54 4.55 0.00
16 3.79 3.75 0.04 3.57 3.55 0.02
17 4.00 4.02 −0.02 4.05 4.06 −0.01
19 4.21 4.19 0.02 4.39 4.42 −0.03
20 4.55 4.57 −0.02 4.51 4.51 0.00
B13 4.17 4.16 0.01 4.03 4.00 0.02
Average 0.02 0.02
aActual cytotoxic activity; 
bpredicted activity by the CoMSIA model with hydrophobic, hydrogen bond donor, and hydrogen bond 
acceptor fields; 
cdifference between the actual and predicted activities; The pIC50 (−log IC50) values were converted from IC50 values.
Colon cancer HT-29 cells
  The CoMSIA model with hydrophobic, hydrogen bond do-
nor, and hydrogen bond acceptor fields gave a cross-vali-
dated coefficient (q
2) value of 0.703 and non-cross-validated 
coefficient (r
2
ncv) value of 0.992 with the optimum number 
of components of 4; SEE, 0.027; and F value, 396.375. The 
q
2 value obtained from this model was higher than those 
from any other CoMFA and CoMSIA models. The predictive 
ability of the model was expressed as r
2
pred with a value 
of 0.929. The predicted pIC50 values and residuals for train-
ing and test sets are shown in Tables 3 and 4, respectively. 
A graph of actual versus predicted pIC50 values for the 
training and test sets is illustrated in Fig. 2.Cytotoxicities and QSAR of B13 Sulfonamides 427
Table 4. Actual versus predicted cytotoxicities (pIC50) of the test set
Compounds
Colon cancer cells (HT-29 cells) Lung cancer cells (A549 cells)
Actual
a Predicted
b Residual
c Actual
a Predicted
b Residual
c
 13 . 7 2 3 . 7 9 −0.07 3.68 3.72 −0.03
10 4.41 4.42 −0.01 4.09 4.23 −0.14
12 4.27 4.24 0.03 4.07 4.00 0.07
18 4.27 4.16 0.12 4.16 4.23 −0.07
Average 0.06 0.08
aActual cytotoxic activity; 
bpredicted activity by the CoMSIA model with hydrophobic and hydrogen bond acceptor fields; 
cdifference 
between the actual and predicted activities; The pIC50 ( −log IC50) values were converted from IC50 values.
Fig. 2. Graph of the actual versus predicted activities for training 
and test set compounds. (A) Colon cancer HT-29 cells. (B) Lung 
cancer A549 cells. The IC50 values were transformed into pIC50 (−log 
IC50) values (●: training set molecules, ▲: test set molecules).
Lung cancer A549 cells
  The CoMSIA model with hydrophobic and hydrogen bond 
acceptor fields was used to calculate the cross-validated co-
efficient (q
2), non-cross-validated coefficient (r
2
ncv), and opti-
mum number component (N) to give values of 0.830, 0.990, 
and 4, respectively. With this model, the predicted r
2 value 
(r
2
pred) was 0.832 and the predicted pIC50 values and re-
siduals of the training set and test set are summarized in 
Tables 3 and 4, respectively. Fig. 2B describes the correla-
tion between the actual versus predicted pIC50 values of the 
compounds in the training and test sets.
DISCUSSION
  A s  d e s c r i b e d  i n  t h e  in vitro bioassay, compound (15) 
showed the most potent activity against both colon cancer 
HT-29 and lung cancer A549 cell lines with IC50 values of 
27.0 and 28.7μM, respectively. B13 sulfonamides with a 
C13H27 alkyl chain (5, 15, 10, 20) showed two or three times 
more potent cytotoxicities than B13 which also had a C13H27 
alkyl chain, suggesting that introduction of a sulfonamide 
group into B13 increased its cytotoxicity. The stereo-
chemistry of 1,3-propandiol was not important for cytotox-
icity in compounds with alkyl chains of the same length, 
although some (1R, 2R)-compounds (12, 13, 15) manifested 
stronger cytotoxicities than the (1S, 2S)-compounds (16, 18, 
20), which had slightly more potent activities than the (1R, 
2S)-compounds (2, 4, 5) and (1S, 2R)-compounds (7, 8, 9). 
The compounds with a para nitro group at the phenyl ring 
and a C3-OH group (13, 15, 18, 20) demonstrated higher 
activities than the compounds without them (3, 5, 8, 10). 
In general, compounds with long alkyl chains (5, 10, 15, 
20) exhibited enhanced activity compared to those with 
short alkyl chains (1, 6, 11, 16). This finding was consistent 
with the reported trend that cytotoxicity increased with an 
increase in the acyl chain length of ceramide [36].
  In the CoMSIA model of colon cancer HT-29 cells, the 
cross-validated coefficient (q
2) value was 0.703 and was con-
sidered sufficiently predictive for validation because it was 
greater than 0.6. The relative contributions of the hydro-
phobic field (44.2%), hydrogen bond donor field (26.9%), and 
hydrogen bond acceptor field (29%) indicated that the phe-
nyl ring and long alkyl chain for hydrophobicity, the hydro-
gen atom of sulfonamide as a hydrogen bond donor, oxygen 
atoms of the C1-OH and sulfone group as hydrogen bond 
acceptors contributed to cytotoxicity. For lung cancer A549, 
the CoMSIA model with hydrophobic and hydrogen bond 
acceptor fields yielded high q
2 (0.830) and r
2
ncv (0.990) val-
ues which represented a precise predictivity for this model. 
The contributions of the hydrophobic field (58.7%) and hy-
drogen bond acceptor field (41.3%) indicated that strong hy-
drophobic ligand-receptor interactions were involved in the 
cytotoxicities of the compounds. The small average residual 
values (0.02) between actual and predicted activities in 
Table 3 demonstrated that the predicted activity from the 
CoMSIA models correlated well with actual activity. The 
test set was used to validate the predictive ability of these 
CoMSIA models and their small average residual values 
(0.06 and 0.08) showed that both models accurately pre-
dicted the cytotoxicities of test set molecules.
  The CoMSIA contour maps illustrate the structural fea-
tures important for potent activity to show regions around 428 SKC Lee, et al
Fig. 3. 3D-contour maps of CoMSIA models. (A) CoMSIA model 
with hydrophobic, hydrogen bond donor, and hydrogen bond 
acceptor fields for colon cancer HT-29 cells. (B) CoMSIA model with 
hydrophobic and hydrogen bond acceptor fields for lung cancer 
A549 cells. Compound (15) is shown within the fields (yellow, 
favorable hydrophobicity; white, unfavorable hydrophobicity; cyan, 
favorable hydrogen bond donor; purple, unfavorable hydrogen bond 
donor; magenta, favorable hydrogen bond acceptor; red, unfavora-
ble hydrogen bond acceptor).
molecules, in which increased or decreased activity was ex-
pected by physicochemical property changes. In Fig. 3, the 
yellow contours indicate regions where a hydrophobic group 
would increase the biological activity, whereas the white 
ones would decrease the activity.
  The cyan and purple contours denote the places where 
a hydrogen bond donor would be favorable and unfavorable, 
respectively. The magenta regions represent areas that are 
favorable for a hydrogen bond acceptor, while red regions 
indicate areas unfavorable for such a group. The molecule 
used in the contour maps is compound (15), which showed 
the most potent cytotoxicity.
  The CoMSIA contour map of colon cancer HT-29 cells 
(Fig. 3A) presents yellow contours at ortho and meta posi-
tions of the phenyl ring. These yellow contours suggest that 
hydrophobic groups at these regions would enhance cytotox-
icity and that the introduction of a naphthyl ring instead 
of a phenyl ring would increase activity. This finding was 
supported by the compounds (1, 6, 11) in which yellow con-
tours were superimposed with oxygen atoms of sulfonamide 
and C1-OH groups to show much lower activities than other 
compounds with IC50 values of 191.5, 183, and 101μM, 
respectively. The cyan contours near the hydrogen atoms 
of sulfonamide in compounds (5, 15) and the C3-OH group 
in compound (20) coincided with regions favorable for a hy-
drogen bond donor and the magenta contours around the 
oxygen atoms of the C1-OH and sulfonamide groups in com-
pounds (5, 15, 20) corresponded to favorable hydrogen bond 
acceptor regions helping to account for their high potency. 
The CoMSIA contour map of lung cancer A549 cells (Fig. 
3B) illustrated yellow contours at ortho and meta positions 
of the phenyl ring and the alkyl chain in compounds (5, 
15, 20), where they were in accord with hydrophobically 
favorable regions to produce strong cytotoxic activities. It 
was also shown that the favorable hydrogen bond acceptor 
regions (magenta contour) were near the oxygen atoms of 
C1-OH and sulfonamide groups, while unfavorable regions 
(red contour) were located around the alkyl side chain in 
compounds (5, 15, 20). These regions correlated well with 
the contour map to explain their potent cytotoxicity.
  In conclusion, compounds (5, 15, 20) exhibited stronger 
cytotoxicities than B13 in both tumor cell lines. The good 
predictivity of the CoMSIA models was illustrated by high 
q
2 (0.703 and 0.830) and r
2
ncv (0.992 and 0.990) coefficient 
values. The small average residual values of the training 
(0.02) and test (0.06 and 0.08) sets indicated that the pre-
dicted activities from CoMSIA models correlated well with 
the actual activities. Cytotoxic assays demonstrated that 
the stereochemistry of 1,3-propandiol was not important for 
activity and that a sulfonamide group and long alkyl chain 
increased the cytotoxicity of the compounds. Furthermore, 
the introduction of a naphthyl ring in place of the phenyl 
ring was suggested to increase hydrophobicity and 
cytotoxicity.
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